Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Beatty, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodkin, D. E.
Right arrow Articles by Beatty, W. W.
NEUROLOGY 1991;41:20
© 1991 American Academy of Neurology

The efficacy of azathioprine in relapsing - remitting multiple sclerosis

D. E. Goodkin, MD, R. C. Bailly, MD, M. L. Teetzen, MD, D. Hertsgaard, PhD and W. W. Beatty, PhD

Mellen Center for Multiple Sclerosis Treatment and Research (Dr. Goodkin). Cleveland Clinic Foundation, Cleveland, OH; Fargo Clinic (Dr. Bailly), Fargo, ND; Grand Forks Clinic (Dr. Teetzen), Grand Forks, ND; 112 D H Research Statistical Consultants, (Dr. Hertsgaard), Fargo, ND; and the Neuropsychiatric Research Institute and the Department of Psychology (Dr. Beatty), North Dakota State University, Fargo, ND.

We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to deterioration in both Ambulation Index and Kurtzke Expanded Disability Status Scale score. This study confirms a modest therapeutic benefit for azathioprine previously reported by other investigators.

Address correspondence and reprint requests to Dr. Donald E. Goodkin, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Area U-10, 9500 Euclid Avenue, Cleveland, OH 44195-5244.

Supported in part by the National Multiple Sclerosis Society (RG-1762-A-1). and medications were supplied by the Burroughs Wellcome Company, Research Triangle Park, NC.

Received April 16, 1990. Accepted for publication in final form June 15,1990.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group
Treatment of pediatric multiple sclerosis and variants
Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. R. Jeffery
Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis
Neurology, December 28, 2004; 63(12_suppl_6): S41 - S46.
[Abstract] [Full Text]

Home page
 Journal of Pharmacy PracticeHome page
T. M. Sievers
New Antiproliferative Immunosuppressive Agents
Journal of Pharmacy Practice, December 1, 2003; 16(6): 401 - 413.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Markovic-Plese, B. Bielekova, N. Kadom, T. P. Leist, R. Martin, J. A. Frank, and H. F. McFarland
Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon {beta}-1b
Neurology, June 10, 2003; 60(11): 1849 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
C. L M Sudlow and C. E Counsell
Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
BMJ, February 15, 2003; 326(7385): 388 - 392.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. H. Noseworthy, P. C. O'Brien, B. G. Weinshenker, J. A. Weis, T. M. Petterson, B. J. Erickson, A. J. Windebank, J. P. Whisnant, K. A. Stolp-Smith, C. M. Harper Jr., et al.
IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial
Neurology, October 24, 2000; 55(8): 1135 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
G. R. Cutter, M. L. Baier, R. A. Rudick, D. L. Cookfair, J. S. Fischer, J. Petkau, K. Syndulko, B. G. Weinshenker, J. P. Antel, C. Confavreux, et al.
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Brain, May 1, 1999; 122(5): 871 - 882.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
T. L. Vollmer
Multiple Sclerosis: New Approaches to Immunotherapy
Neuroscientist, March 1, 1996; 2(2): 127 - 136.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. Rudick, S. Medendorp, M Namey, S Boyle, and J Fischer
Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains
Multiple Sclerosis, November 1, 1995; 1(3): 150 - 155.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. B. Tenser, K. A. Hay, and J. A. Aberg
Immunoglobulin G Immunosuppression of Multiple Sclerosis: Suppression of All Three Major Lymphocyte Subsets
Arch Neurol, April 1, 1993; 50(4): 417 - 420.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by AAN Enterprises, Inc.